Llorente/Sandvig publish potential biomarkers for prostate cancer

Llorente (left) and Sandvig

Alicia Llorente and Kirsten Sandvig, Department of Biochemistry, Institute for Cancer Research and Centre for Cancer Biomedicine, have recently published in Molecular and Cellular Proteomics (impact factor 8.4) a proteomic analysis of microvesicles released from a human prostate cancer cell line. Most of the 266 proteins identified have previously been reported to be present in vesicles released from other cell types, but several proteins seem to be specific for prostate cancer cells. Since microvesicles can reach biological fluids, these proteins are thus potentially useful as new non invasive biomarkers for detection, diagnosis and/or prognosis of prostate cancer.

Links

Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.
Sandvig K, Llorente A.
Mol Cell Proteomics. 2012 Mar 28. [Epub ahead of print]

Home page of Kirsten Sandvig's group - Intracellular transport

Sandvig's mini CV (including publications)

Department of Biochemistry

Centre for Cancer Biomedicine

Recent publications

From major journals, first or last author from the Institute for Cancer Research

Rakaee M, Nassar AH, Tafavvoghi M, Jabar F, Bou Farhat E, Adib E, Andersen S, Busund LR, Pøhl M, Helland Å, Gusev A, Ricciuti B, Sholl LM, Donnem T, Kwiatkowski DJ (2026)
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2025.6430, PubMed 41678173

Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA (2026)
Common gene mutations in 103 authenticated colorectal cancer cell lines
Oncogenesis, 15 (1), 8
DOI 10.1038/s41389-026-00599-0, PubMed 41593049

Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA (2026)
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer
Breast, 86, 104704 (in press)
DOI 10.1016/j.breast.2026.104704, PubMed 41581361

More selected publications

Most recent publications

Rakaee M, Nassar AH, Tafavvoghi M, Jabar F, Bou Farhat E, Adib E, Andersen S, Busund LR, Pøhl M, Helland Å, Gusev A, Ricciuti B, Sholl LM, Donnem T, Kwiatkowski DJ (2026)
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2025.6430, PubMed 41678173

Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium (2026)
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial
Acta Oncol, 65, 90-96
DOI 10.2340/1651-226X.2026.45086, PubMed 41664938

Davidson B, Stričak LM, Holth A, Torgunrud A, Wohlschlaeger J, Tötsch M, Bassarova A (2026)
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosis
Virchows Arch (in press)
DOI 10.1007/s00428-026-04438-w, PubMed 41656400

More publications

Annual summary of publications